Clinical trial
Safety and Efficacy of Exenatide as Monotherapy
NCT00381342 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00381342 |
|---|---|
| Title | Safety and Efficacy of Exenatide as Monotherapy |
| Official title | Safety and Efficacy of Exenatide as Monotherapy in Drug Naive Patients With Type 2 Diabetes |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | exenatide, placebo |
| Enrollment | 233 |
| Start date | Sep 1, 2006 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Sep 27, 2006 |
| Last update posted | Feb 23, 2015 |
| Countries | India, Puerto Rico, Romania, Russia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: